You are here

FDA Approves Brimonidine Tartrate, Glaucoma Treatment

FORT WORTH, Texas, Sept. 16 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration today approved Falcon Pharmaceuticals, Ltd.'s (Falcon) generic brimonidine tartrate ophthalmic solution 0.2% (brimonidine). Falcon is an affiliate of Alcon, Inc. , the world's leading eye care company. Brimonidine is therapeutically equivalent to Alphagan* and is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The drug is available immediately, and comes in a Drop-tainer** dispenser in three sizes: 5mL, 10mL and 15mL. At the time of manufacture, the product will have a 24-month shelf life.

Although Falcon's marketing and sales efforts will target wholesale distributors, retail pharmacies, hospitals and managed care organizations, it will also communicate the availability of brimonidine directly to ophthalmologists.

Falcon is the largest manufacturer and marketer of generic drugs for the eye and ear in the United States. Alcon is the world's leading eye care company and has been dedicated to the ophthalmic industry for more than 50 years. It develops, manufactures and markets the widest selection of pharmaceuticals, surgical products, contact lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye.

Source: Alcon, Inc.

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Disrupting Gut Microbiome Could Be Key